Fumaric acid 30mg tablets
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(3)
Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 14 · Randomised trials: 7 · 1950–2025
Showing the 50 most relevant studies, sorted by most relevant.
David J. Smith
Irish Journal of Medical Science (1971 -), 2016
- Chronic Disease
- Dermatologic Agents
- Fumarates
Malik MI, Capucchio MT, Tunkala BZ, et al.
2025
- Rumen
- Ruminants
- Fumarates
Manuj Ahuja, Navneet Ammal Kaidery, Lichuan Yang, et al.
Journal of Neuroscience, 2016
- Cell Line, Transformed
- Disease Models, Animal
- Fumarates
Ralf Gold, Ralf A. Linker, Martin Stangel
Clinical Immunology, 2011
- Clinical Trials as Topic
- Fumarates
- Immunosuppressive Agents
Thaçi D, Pinter A, Sebastian M, et al.
2024
- Psoriasis
- Fumarates
- Antibodies, Monoclonal, Humanized
Ulrich Mrowietz, Peter J. Morrison, Ina Suhrkamp, et al.
Trends in Pharmacological Sciences, 2017
- Dimethyl Fumarate
- Dermatologic Agents
- Fumarates
Qing Xu, Shuang Li, He Huang, et al.
Biotechnology Advances, 2012
- Fermentation
- Bacteria
- Biotechnology
G. Holzer, M. Hoke, S. Sabeti-Sandor, et al.
Journal of the European Academy of Dermatology and Venereology, 2020
- Cardiovascular Diseases
- Psoriasis
- Dermatologic Agents
Ralf A. Linker, De-Hyung Lee, Sarah Ryan, et al.
Brain, 2011
- Nogo Proteins
- Aldehyde Reductase
- Antigens, Differentiation
E. Racker
Biochimica et Biophysica Acta, 1950
- Acids
- Aconitic Acid
- Ferrous Compounds
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Investigational
Major interactions
None known
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
3 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Proteins and enzymes this drug interacts with in the body
PMID:16914093 PMID:8666937
Primarily signals through the JAK-STAT pathway after interaction with its receptor IFNGR1 to affect gene regulation .
PMID:8349687
Upon IFNG binding, IFNGR1 intracellular domain opens out to allow association of downstream signaling components JAK2, JAK1 and STAT1, leading to STAT1 activation, nuclear translocation and transcription of IFNG-regulated genes. Many of the induced genes are transcription factors such as IRF1 that are able to further drive regulation of a next wave of transcription .
PMID:16914093
Plays a role in class I antigen presentation pathway by inducing a replacement of catalytic proteasome subunits with immunoproteasome subunits .
PMID:8666937
In turn, increases the quantity, quality, and repertoire of peptides for class I MHC loading .
PMID:8163024
Increases the efficiency of peptide generation also by inducing the expression of activator PA28 that associates with the proteasome and alters its proteolytic cleavage preference .
PMID:11112687
Up-regulates as well MHC II complexes on the cell surface by promoting expression of several key molecules such as cathepsins B/CTSB, H/CTSH, and L/CTSL .
PMID:7729559
Participates in the regulation of hematopoietic stem cells during development and under homeostatic conditions by affecting their development, quiescence, and differentiation (By similarity)
ATC D05AX01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Fumaric acid
Additional database identifiers
ChemSpider
10197150
BindingDB
26122
PDB
FUM
ZINC
ZINC000003860193
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5438
GenAtlas
IFNG
GeneCards
IFNG
GenBank Gene Database
X13274
GenBank Protein Database
32692
UniProt Accession
IFNG_HUMAN
GenBank Gene Database
X89038
GenBank Protein Database
1491644
UniProt Accession
MDH_CHLAA
GenBank Gene Database
AE014299
GenBank Protein Database
24346572
UniProt Accession
FCCA_SHEON
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6984
GenAtlas
ME2
GeneCards
ME2
GenBank Gene Database
M55905
GenBank Protein Database
187300
UniProt Accession
MAOM_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3579
GeneCards
FAH
UniProt Accession
FAAA_HUMAN
GenBank Gene Database
AJ132010
GenBank Protein Database
4539587
UniProt Accession
FCCA_SHEFR
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q139857), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.